Return Peptide Library
Albiglutide
BLevel 1 evidenceAlbiglutide
GLP-1 and incretin receptor agonists
Basic Information
Categories
GLP-1 receptor agonist
Overview
Once-weeklong long-acting GLP-1RA, developed by GSK, commercially withdrawn after 2017 years.
Efficacy Rating
GLP-1 RA, type 2 diabetes mellitus, discontinued
Evidence Level
Grade B
Evidence Type
No data available
Confidence
No data available
China Regulatory Status
Cosmetic Ingredient Directory
No data available
Food/Supplements
No data available
Medicine
No data available
Similar Peptide Recommendations
Semaglutide
Ecenoglutide
BGLP-1 and incretin receptor agonists
GLP-1, weight loss, biased agonist
Enisamitide
Enisamipide
BGLP-1 and incretin receptor agonists
GLP-1/GIP agonist, weight loss
Exenatide
Exenatide
BGLP-1 and incretin receptor agonists
Metabolic health, FDA-approved, GLP-1
Mazdutide
Mazdutide
BGLP-1 and incretin receptor agonists
GLP-1/Glucagon-like Receptor Agonists for Weight Loss
Disclaimer
The content on this platform is for educational and informational purposes only and does not constitute medical advice, formulation guidance, or a guarantee of regulatory compliance. All efficacy claims are labeled with their evidence level; please consult a professional before making any decisions.